InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1728328
Sentiment: neutral
Topics: corporate-disclosure, financial-reporting
TL;DR
InMed Pharma filed an 8-K on Nov 14th, reporting corporate updates and financials. Check their Vancouver HQ details.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on November 14, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C., Canada, V6C 3E8. The company's telephone number is (604) 669-7207.
Why It Matters
This 8-K filing serves as a public record of InMed Pharmaceuticals Inc.'s corporate activities and financial reporting, providing transparency for investors and stakeholders.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer
- November 14, 2024 (date) — Date of earliest event reported
- Vancouver, B.C., Canada (location) — Principal Executive Offices
- ( 604 ) 669-7207 (phone_number) — Company's telephone number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The exact date of the earliest event reported is November 14, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C., Canada, V6C 3E8.
What is the company's telephone number?
The company's telephone number, including area code, is (604) 669-7207.
What is the Commission File Number for InMed Pharmaceuticals Inc.?
The Commission File Number for InMed Pharmaceuticals Inc. is 001-39685.
What are the main items reported in this 8-K filing?
This 8-K filing reports a Regulation FD Disclosure and Financial Statements and Exhibits.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-11-14 19:56:36
Filing Documents
- ea0221397-8k_inmed.htm (8-K) — 35KB
- ea022139701ex99-1_inmed.htm (EX-99.1) — 82KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-24-098655.txt ( ) — 320KB
- inm-20241114.xsd (EX-101.SCH) — 3KB
- inm-20241114_lab.xml (EX-101.LAB) — 33KB
- inm-20241114_pre.xml (EX-101.PRE) — 22KB
- ea0221397-8k_inmed_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated November 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: November 14, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2